At the International AIDS Society 2025 Conference in Kigali, Rwanda, ViiV Healthcare is set to showcase groundbreaking data that underscores the real-world impact of their long-acting injectable treatments for HIV. These innovative therapies, comprising the combination of Vocabria and Rekambys (cabotegravir + rilpivirine LA), are redefining the way HIV is managed and treated globally.

The new findings highlight the effectiveness of these long-acting injectables, demonstrating their advantages over daily oral medications for both treatment and prevention of HIV. Dr. Jean van Wyk, Chief Medical Officer at ViiV Healthcare, commented on the findings, stating, "Our extensive insights reflect how these injectables are transforming HIV care, offering flexibility and meeting the diverse needs of those affected by the virus."

Key Highlights from IAS 2025 Presentations

The data to be presented at IAS 2025 include critical evaluations on several fronts, such as patient preferences for long-acting therapies, effectiveness studies, and real-world outcomes across various demographics.

1. **Patient Choice and Satisfaction**: New phase IIIb studies examine how treatment-naive adults respond to switching from daily regimens to the long-acting CAB+RPV LA after achieving rapid viral suppression. Initial findings indicate a strong preference for transitioning to injectables, significantly enhancing treatment satisfaction.

2. **Real-World Effectiveness**: Data from multiple studies, including the ongoing COMBINE-2 trial and two-year insights from CARLOS and BEYOND, reveal strong adherence and satisfaction rates with CAB+RPV LA. Special analyses from the OPERA cohort focus on treatment-experienced individuals starting their therapy journey with high viral loads.

3. **PrEP Implementation Insights**: New data from the PILLAR and EBONI studies showcase how cabotegravir for pre-exposure prophylaxis (PrEP) has been effectively implemented, particularly among high-risk populations such as men who have sex with men and transgender individuals.

Expanded Efficacy Data on Antiretroviral Treatments

Additionally, the conference will present findings on the efficacy of dolutegravir and lamivudine (Dovato) in achieving rapid viral suppression across diverse groups, including those with transmitted drug-resistance mutations. With further studies from D2ARLING and SUNGURA, ViiV aims to deepen the understanding of treatment strategies for various populations.

Understanding Community Impact on Treatment Outcomes

A particularly notable aspect of this year's presentations will be the interim results from the Positive Perspectives study. These highlight the vital role community involvement plays in shaping treatment outcomes, linking shared decision-making with enhanced health and treatment satisfaction.

As ViiV Healthcare continues to pioneer advancements in HIV treatment and prevention, their presentations at IAS 2025 are set to spotlight the significance of choice and community engagement in improving the lives of those living with HIV. This bold step indicates a promising shift towards more personalized, effective care strategies.